Evidence map›Paper›PMID 28442904›Full record

ArticleInternational journal of nanomedicine2017

Anti-FGFR1 aptamer-tagged superparamagnetic conjugates for anticancer hyperthermia therapy.

Przemysław M Jurek, Konrad Zabłocki, Urszula Waśko, Maciej P Mazurek, Jacek Otlewski, Filip Jeleń

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Aptamers in Osteosarcoma: New Paths for Diagnosis and Treatment.Anti-cancer agents in medicinal chemistry · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Przemysław M JurekDepartment of Protein Engineering, Faculty of Biotechnology, University of Wrocław, Poland.
Konrad ZabłockiDepartment of Protein Engineering, Faculty of Biotechnology, University of Wrocław, Poland.
Urszula WaśkoDepartment of Protein Engineering, Faculty of Biotechnology, University of Wrocław, Poland.
Maciej P MazurekDepartment of Protein Engineering, Faculty of Biotechnology, University of Wrocław, Poland.
Jacek OtlewskiDepartment of Protein Engineering, Faculty of Biotechnology, University of Wrocław, Poland.
Filip JeleńDepartment of Protein Engineering, Faculty of Biotechnology, University of Wrocław, Poland.
University of Wrocław · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Compounds that recognize and strongly bind to molecular targets are one of the cornerstones of modern pharmaceutics. Work has been ongoing for the past 25 years on the therapeutic use of aptamers, nucleic acid molecules, whose three-dimensional structure is the result of interactions between complementary base pairs. The aptamers selection methods allow the oligonucleotides which bind the molecular target in its native environment to be quickly isolated from a large library of random oligonucleotides. The possibilities presented for aptamers in the field of targeted therapy require the application of effective carriers to counter the renal clearance effect and/or functional cargo to exert therapeutic action if the aptamer is only used as a targeting moiety. Lately, a material gaining ground in biomedical research is iron oxide particles, which exhibit a superparamagnetic characteristic at nanoscale levels. This allows the iron oxide nanoparticles to convert external magnetic energy into heat, a mechanism known as hyperthermy, and efficiently supports conventional oncological treatment. In this study, we describe an experimentally confirmed functional model of targeted anticancer hyperthermia therapy. Using the systematic evolution of ligands by exponential enrichment technique, we selected a DNA aptamer that specifically binds to the extracellular domain of recombinant fibroblast growth factor receptor type-1 (FGFR1) with a nanomolar dissociation constant. The chosen target plays an important role in many crucial cellular processes and is also considered a candidate protein that is involved in tumor initiation, survival and progression. Next, we combined the selected aptamer with iron oxide nanoparticles to produce aptamer superparamagnetic conjugates (ASCs). Finally, we found that targeted ASCs selectively destroy FGFR1-overexpressing human osteosarcoma cells U2OS upon magnetic field irradiation.

Indexed as

Antineoplastic AgentsAptamers, NucleotideAvidinCell Line, TumorDrug Screening Assays, AntitumorFerrosoferric OxideHumansHyperthermia, InducedLigandsMagnetic Field TherapyMagnetite NanoparticlesMolecular Targeted TherapyNeoplasmsReceptor, Fibroblast Growth Factor, Type 1Antineoplastic AgentsAptamers, NucleotideAvidinFerrosoferric OxideFGFR1 protein, humanLigandsMagnetite NanoparticlesReceptor, Fibroblast Growth Factor, Type 1aptamersiron oxide magnetic nanoparticlesnanoparticlestargeted cancer therapytargeted hyperthermia

Identifiers

PMID28442904
PMCPMC5396944
OpenAlexW2607381644

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.